Show results for
Refine by
T Standard Polystyrene Disposable Cell Suppliers Serving Argentina
33 companies found
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
This technology arms the patient’s own T cells with CARs, which enable them to “seek and destroy” cancer ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
based inOxford, UNITED KINGDOM
Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...
based inBielefeld, GERMANY
PlasmidFactory GmbH & Co. KG is a globally active biopharmaceutical company, founded in Bielefeld, Germany, in 2000. The leading contract manufacturing organization (CMO) for plasmid and minicircle DNA has a strong customer base in the fields of ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
TC BioPharm’s cell banks have been developed as a resource for clinical development of cost-effective, safe and efficacious therapeutic treatments and ultimately, the ability to treat more patients. These T cell banks provide TC BioPharm with ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
CAR T-cell therapy is the engineering of a patient’s T cells, a type of white blood cell. A small portion of these cells are collected, from a patient’s blood sample, and re-engineered to produce chimeric antigen receptors (CAR’s) ...
based inShirley, NEW YORK (USA)
Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human ...
CRISPR/Cas9 technology has been used as a genome-editing tool for multiple cell lines, such as tumor cell line and embryonic stem cell lines. Primary T cell, as an important class of immune cells system, play an extremely important role in immunity ...
based inPlanegg, GERMANY
TQ Therapeutics GmbH is pioneering a novel approach to cell and gene therapy with its TQx platform, which transforms the production of cellular therapies into a rapid, automated process that occurs at the patient's side. This method leverages ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Patients eligible for clinical trials with ACTengine® product candidates have a portion of their white blood cells collected using a well-established process called leukapheresis, a procedure in which a fraction of the white blood cells of a ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T; Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo; Clear anti-cancer efficacy in an orthotopic model; Smaller number of 4th ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
based inPiscataway, NEW JERSEY (USA)
Genscript is the world’s leading biotech company providing life sciences services and products. With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, we are internationally recognized as a leading ...
based inPlymouth Meeting, PENNSYLVANIA (USA)
INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat ...
INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA smart devices. Once inside the cell, the DNA plasmids enable the cell to produce ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ...
based inDallas, TEXAS (USA)
Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C and GT production and ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
based inCleveland, OHIO (USA)
Cellular Technology Limited (CTL) is a biotechnology company headquartered in Shaker Heights, a suburb of Cleveland, Ohio, with locations and distributors worldwide. We presently have around 180 full-time employees. Our company is family owned and ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
There are many laboratories developing CAR T-cell therapies. Genekam has a number of kits to develop CAR T-Cell therapy e.g. isolate large number of T cells (CD4 / CD8) from blood or other source. This isolation kit will generate larger number of ...
based inFreiburg, GERMANY
Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other ...
CellGenix Recombinant Human FGF-2, also known as bFGF, reliable improves proliferation of mesenchymal stem cells (MSCs). It in addition supports proliferation and differentiation of chondrocytes and supports propagation of undifferentiated ...